Detail of "208265-92-3"

Reference

Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients

All Rights Reserved. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Martino, Massimo; Pratico, Giulia; Messina, Giuseppe; Irrera, Giuseppe; Massara, Elisabetta; Console, Giuseppe; Iacopino, Pasquale (Bone Marrow Transplant Unit, Azienda Ospedaliera 'Bianchi-Melacrino-Morelli', Reggio Calabria, Italy). European Journal of Haematology, 77(5), 410-415 (English) 2006 Blackwell Publishing Ltd. CODEN: EJHAEC. ISSN: 0902-4441. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) We undertook a comparative study of Pegfilgrastim vs. Filgrastim after high-dose melphalan and autologous peripheral blood stem cell transplantation (APBSCT) in multiple myeloma (MM) patients. Thirty-seven consecutive patients were randomly assigned to receive a single 6 mg dose of Pegfilgrastim on day 1 post-transplant (n = 18 patients) vs. daily s.c. injections of Filgrastim 5 mg/kg (n = 19 patients) starting on day 5 post-transplant. The median duration of grade 4 neutropenia in the Pegfilgrastim and Filgrastim groups was 5 and 6 d, resp. (P = ns). The results for the two groups were also not significantly different for time to neutrophil and platelet recovery, but incidence of febrile neutropenia (61.1% vs. 100%, P = 0.003) and duration of febrile neutropenia (1.5 d vs. 4 d, P = 0. 148-82-3 and 208265-92-3 are also in the experiment.005), were lower in the Pegfilgrastim arm. After initial hematopoietic reconstitution, we obsd. significantly higher value of leukocytes ′ 109 L on day 15 (6.0 vs. 2.7, P = 0.004), in the Pegfilgrastim group compared with the Filgrastim group. This study shows that a single injection Pegfilgrastim can be used with safety and efficacy similar to those provided by daily injections of Filgrastim and it is assocd. with a decrease incidence of infectious events after APBSCT in MM patients. .

PEGylated proteins as cancer therapeutics

All Rights Reserved. PEGylated proteins as cancer therapeutics. Morpurgo, Margherita; Pasut, Gianfranco; Veronese, Francesco M. ( Department of Pharmaceutical Science, University of Padova, Padua 35131, Italy). Delivery of Protein and Peptide Drugs in Cancer, 85-110. Edited by: Torchilin, Vladimir P. Imperial College Press: London, UK. ISBN: 1-86094-627-5(English) 2006. CODEN: 69IGVE. DOCUMENT TYPE: Conference; General Review CA Section: 1 (Pharmacology) A review focuses on PEGylated enzymes and antibodies having potential or established anticancer applications.There are some commonly used reagents with their cas registry numbers 208265-92-3 and 215647-85-1 in this article. Some of these products are already marketed, while others are under preclin. or phases I-III clin. trials. .